Adjuvant Therapy of Breast Cancer

Abeloff, 1990, Sixteen week dose intensive adjuvant chemotherapy for operable breast cancer with ten or more positive nodes, Proc Am Soc Clin Oncol, 9, 24 Arriagada, 1991, Adjuvant chemotherapy in early breast cancer and incidence of new primary malignancies, Lancet, 338, 535, 10.1016/0140-6736(91)91100-9 Barrett-Connor, 1991, Estrogen and coronary heart disease in women, JAMA, 265, 1861, 10.1001/jama.1991.03460140089033 Bianco, 1991, Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer, Br J Cancer, 63, 799, 10.1038/bjc.1991.177 Boccardo, 1990, Chemotherapy vs tamoxifen vs chemotherapy plus tamoxifen in node positive, estrogen receptor positive breast cancer patients. Results of a multicentric Italian study, J Clin Oncol, 8, 1310, 10.1200/JCO.1990.8.8.1310 Bonadonna, 1981, Dose-response effect of adjuvant chemotherapy in breast cancer, N Engl J Med, 304, 10, 10.1056/NEJM198101013040103 Bonadonna, 1985, Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer, Breast Cancer Res Treat, 5, 95, 10.1007/BF01805984 Brincker, 1987, Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer, J Clin Oncol, 5, 1771, 10.1200/JCO.1987.5.11.1771 Brüning, 1990, Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer, Br J Cancer, 61, 308, 10.1038/bjc.1990.58 Brunner, 1989, Adjuvant therapies in breast cancer and quality of life: A critical review of the TWiST concept, Recent Results Cancer Res, 115, 239, 10.1007/978-3-642-83337-3_35 Budman, 1992, Initial findings of CALGB 8541: A dose and dose intensity trial of cyclophosphamide, doxorubicin, and 5-fluorouracil as adjuvant treatment of Stage II, node +, female breast cancer, Proc Am Soc Clin Oncol, 11, 51 Bush, 1988, Cholesterol, lipoproteins, and coronary heart disease in women, Clin Chem, 334, B60 Buzzoni, 1991, Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes, J Clin Oncol, 9, 2134, 10.1200/JCO.1991.9.12.2134 Carpenter, 1991, Prospective randomized comparison of cyclophosphamide, doxorubicin (Adriamycin) and fluorouracil (CAF) vs. cyclophosphamide, methotrexate, and fluorouracil (CMF) for breast cancer with positive axillary nodes: A Southeastern Cancer Study Group Study, Proc Am Soc Clin Oncol, 10, 45a 1988, Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer, Br J Cancer, 57, 604, 10.1038/bjc.1988.137 Curtis, 1990, Leukemia following chemotherapy for breast cancer, Cancer Res, 50, 2741 Curtis, 1992, Risk of leukemia after chemotherapy and radiation treatment for breast cancer, N Engl J Med, 326, 1745, 10.1056/NEJM199206253262605 Desch, 1993, Should the elderly receive chemotherapy for node-negative breast cancer? A cost-effectiveness analysis examining total and active life-expectancy questions, J Clin Oncol, 11, 777, 10.1200/JCO.1993.11.4.777 Dnistrian, 1983, Endocrine consequences of CMF adjuvant therapy in premenopausal and postmenopausal breast cancer patients, Cancer, 51, 803, 10.1002/1097-0142(19830301)51:5<803::AID-CNCR2820510509>3.0.CO;2-V Dombernowsky, 1988, Adjuvant therapy of premenopausal and menopausal high-risk breast cancer patients, Acta Oncol, 6a, 691, 10.3109/02841868809091771 Donovan, 1989, Measuring quality of life in cancer patients, J Clin Oncol, 7, 959, 10.1200/JCO.1989.7.7.959 1992, Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women, Lancet, 339, 1 Fisher, 1990, J Clin Oncol, 8, 1483, 10.1200/JCO.1990.8.9.1483 Fisher, 1986, Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project trial, J Clin Oncol, 4, 459, 10.1200/JCO.1986.4.4.459 Fisher, 1990, J Clin Oncol, 8, 1005, 10.1200/JCO.1990.8.6.1005 Fisher, 1989, Doxorubicin-containing regimens for the treatment of Stage II breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience, J Clin Oncol, 7, 572, 10.1200/JCO.1989.7.5.572 Fisher, 1979, L-Phenylalanine mustard (L-PAM) in the management of premenopausal patients with primary breast cancer: Lack of association of disease-free survival with depression of ovarian function, Cancer, 44, 847, 10.1002/1097-0142(197909)44:3<847::AID-CNCR2820440309>3.0.CO;2-3 Fornander, 1989, Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers, Lancet, 1, 117, 10.1016/S0140-6736(89)91141-0 Fugh-Berman, 1992, Tamoxifen: Disease prevention or disease substitution?, Lancet, 340, 1143, 10.1016/0140-6736(92)93161-F Gasparini, 1993, Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients, J Natl Cancer Inst, 85, 1206, 10.1093/jnci/85.15.1206 Gelber, 1986, The concept of an overview of cancer clinical trials with special emphasis on early breast cancer, J Clin Oncol, 4, 1696, 10.1200/JCO.1986.4.11.1696 Gelber, 1989, Methods for assessing treatment efficacy in trials for adjuvant therapy for breast cancer, 211, 10.1007/978-3-642-83337-3_31 Gelber, 1992, Reporting and interpreting adjuvant therapy clinical trials, J Natl Cancer Inst Monogr, 11, 59 Gelber, 1993, Adjuvant therapy for breast cancer: Understanding the Overview, J Clin Oncol, 11, 580, 10.1200/JCO.1993.11.3.580 Gelber, 1992, Quality of life in clinical trials of adjuvant therapies, J Natl Cancer Inst Monogr, 11, 127 Gelman, 1987, A reanalysis of dose intensity for adjuvant chemotherapy trials in Stage II breast cancer, SAKK Bulletin, 1, 10 Gianni, 1992, Growth factor-supported high-dose sequential (HDS) adjuvant chemotherapy in breast cancer with >10 positive nodes, Proc Am Soc Clin Oncol, 11, 68 Glick, 1992, Adjuvant therapy for primary breast cancer, J Natl Cancer Inst, 84, 1479, 10.1093/jnci/84.19.1479 Goldenberg, 1985, Antagonism of the cytocidal activity and uptake of melphalan by tamoxifen in human breast cancer cells in vitro, Biochemical Pharmacology, 34, 763, 10.1016/0006-2952(85)90755-5 Goldhirsch, 1989, Adjuvant chemo-endocrine therapy or endocrine therapy alone for postmenopausal patients: Ludwig studies III and IV, 153, 10.1007/978-3-642-83337-3_22 Greene, 1986, Melphalan may be a more potent leukemogen than cyclophosphamide, Ann Intern Med, 105, 360, 10.7326/0003-4819-105-3-360 Haas, 1987, Risk of leukaemia in ovarian tumour and breast cancer patients following treatment by cyclophosphamide, Br J Cancer, 55, 213, 10.1038/bjc.1987.40 Henderson, 1991, Adjuvant systemic therapy for early breast cancer, 427 Henderson, 1988, Dose-response in the treatment of breast cancer: A critical review, J Clin Oncol, 6, 1501, 10.1200/JCO.1988.6.9.1501 Herring, 1986, Second neoplasms after adjuvant chemotherapy for operable breast cancer, Am J Clin Oncol, 9, 269, 10.1097/00000421-198606000-00018 Hillner, 1991, Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer, N Engl J Med, 324, 160, 10.1056/NEJM199101173240305 Hillner, 1993, Assessing the cost effectiveness of adjuvant therapies in early breast cancer using a decision analysis model, Breast Cancer Res Treat, 25, 97, 10.1007/BF00662134 Holdener, 1984, Remaining problems of adjuvant chemotherapy in breast cancer: Second malignant neoplasms in operable carcinoma of the breast, 188, 10.1007/978-3-642-82357-2_24 Holmes, 1991, Phase II trial of taxol: An active drug in metastatic breast cancer, J Natl Cancer Inst, 83, 1797, 10.1093/jnci/83.24.1797-a Hryniuk, 1986, Analysis of dose intensity for adjuvant chemotherapy trials in Stage II breast cancer, J Clin Oncol, 4, 1162, 10.1200/JCO.1986.4.8.1162 Hug, 1985, Tamoxifen-citrate counteracts the antitumor effects of cytotoxic drugs in vitro, J Clin Oncol, 3, 1672, 10.1200/JCO.1985.3.12.1672 1990, Late effects of adjuvant oophorectomy and chemotherapy upon breast cancer patients, Ann Oncol, 1, 30, 10.1093/oxfordjournals.annonc.a057670 Jensen, 1990, Influence of menopause on serum lipids and lipoproteins, Maturitas, 12, 321, 10.1016/0378-5122(90)90012-U Jones, 1993, Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: Pharmacodynamic evaluation of carmustine, J Natl Cancer Inst, 85, 640, 10.1093/jnci/85.8.640 Jones, 1993, Quantum leaps in treatment of high-risk breast cancer? Prove it!, Eur J Cancer, 29A, 1488, 10.1016/0959-8049(93)90027-D Jordan, 1987, Endocrine effects of adjuvant chemotherapy and long-term tamoxifen on node-positive patients with breast cancer, Cancer Res, 47, 624 Kännel, 1976, Menopause and risk of cardiovascular disease: The Framingham study, Ann Intern Med, 85, 447, 10.7326/0003-4819-85-4-447 Kaufmann, 1993, Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer, J Clin Oncol, 11, 454, 10.1200/JCO.1993.11.3.454 Kaufmann, 1989, Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer, J Clin Oncol, 7, 1113, 10.1200/JCO.1989.7.8.1113 Kleerekoper, 1990, Evaluation and treatment of postmenopausal osteoporosis, 151 Kyle, 1982, Second malignancies associated with chemotherapeutic agents, Semin Oncol, 9, 131 Lavey, 1990, Impact on second malignancy risk of the combined use of radiation and chemotherapy for lymphomas, Cancer, 66, 80, 10.1002/1097-0142(19900701)66:1<80::AID-CNCR2820660116>3.0.CO;2-9 Levine, 1988, Quality of life in Stage II breast cancer: An instrument for clinical trials, J Clin Oncol, 6, 1810, 10.1200/JCO.1988.6.12.1798 Lindsay, 1980, Prevention of spinal osteoporosis in oophorectomised women, Lancet, 2, 1151, 10.1016/S0140-6736(80)92592-1 Love, 1989, Tamoxifen therapy in primary breast cancer: Biology, efficacy, and side effects, J Clin Oncol, 7, 803, 10.1200/JCO.1989.7.6.803 Marcus, 1985, Menstrual function and bone mass in elite women distance runners: Endocrine and metabolic features, Ann Intern Med, 102, 158, 10.7326/0003-4819-102-2-158 Mehta, 1991, Endocrine profile in breast cancer patients receiving chemotherapy, Breast Cancer Res Treat, 20, 125, 10.1007/BF01834642 McDonald, 1991, Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee, Br Med J, 303, 435, 10.1136/bmj.303.6800.435 McGuire, 1992, Prognostic factors and treatment decisions in axillary-nodenegative breast cancer, N Engl J Med, 326, 1756, 10.1056/NEJM199206253262607 Misset, 1992, Ten year results of the French trial comparing adriamycin, vincristin, S-flour our acine, and cyclophosphamide to standard CMF as adjuvant therapy for node-positive breast cancer, Proc Am Soc Clin Oncol, 11, 55 Moinpour, 1989, Quality of life end points in cancer clinical trials: Review and recommendations, J Natl Cancer Inst, 81, 485, 10.1093/jnci/81.7.485 Moliterni, 1990, CMF plus or minus Adriamycin in the adjuvant treatment of breast cancer with 1 to 3 positive nodes, Proc Am Soc Clin Oncol, 9, 19 Mouridsen, 1988, Adjuvant treatment of postmenopausal patients with high risk primary breast cancer: Results from the Danish adjuvant trials DBCG 77 C and DBCG 82 C, Acta Oncol, 27, 699, 10.3109/02841868809091772 Nayfield, 1991, Potential role of tamoxifen in prevention of breast cancer, J Natl Cancer Inst, 83, 1450, 10.1093/jnci/83.20.1450 1990, Treatment of early-stage breast cancer, JAMA, 65, 391 Norton, 1986, The Norton-Simon hypothesis revisited, Cancer Treatment Reports, 70, 163 Osborne, 1990, Autocrine and paracrine growth regulation of breast cancer: Clinical implications, Breast Cancer Res Treat, 15, 3, 10.1007/BF01811884 Osborne, 1989, Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens, J Clin Oncol, 7, 710, 10.1200/JCO.1989.7.6.710 Padmanabhan, 1986, Mechanism of action of adjuvant chemotherapy in early breast cancer, Lancet, 2, 411, 10.1016/S0140-6736(86)92131-8 Pearson, 1989, Endocrine versus endocrine plus five-drug chemotherapy in postmenopausal women with stage II estrogen receptor-positive breast cancer, Cancer, 64, 1819, 10.1002/1097-0142(19891101)64:9<1819::AID-CNCR2820640910>3.0.CO;2-N Peters, 1993, High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer, J Clin Oncol, 11, 1132, 10.1200/JCO.1993.11.6.1132 Pinedo, 1993, Dose effect relationship in breast cancer, Ann Oncol, 4, 351, 10.1093/oxfordjournals.annonc.a058513 Pourquier, 1978, Adjuvant chemotherapy of breast cancer: Is it a direct cytotoxic or has it an indirect hormone effect?, Int J Radiat Oncol Biol Phys, 4, 917, 10.1016/0360-3016(78)90058-5 Raisz, 1989, Pathogenesis, prevention, and treatment of osteoporosis, Annu Rev Med, 40, 251, 10.1146/annurev.me.40.020189.001343 Redmond, 1983, The methodologic dilemma in retrospectively correlating the amount of chemotherapy received in adjuvant therapy protocols with disease-free survival, Cancer Treatment Reports, 67, 519 Richards, 1990, Adjuvant chemotherapy, methotrexate, and fluorouracil in patients with axillary node-positive breast cancer: An update of the Guy’s/Manchester trial, J Clin Oncol, 8, 2032, 10.1200/JCO.1990.8.12.2032 Richelson, 1984, Relative contributions of aging and estrogen deficiency to postmenopausal bone loss, N Engl J Med, 311, 1273, 10.1056/NEJM198411153112002 Riggs, 1986, Involutional osteoporosis, N Engl J Med, 214, 1676, 10.1056/NEJM198606263142605 Rivkin, 1990, Adjuvant combination chemotherapy (CMFVP) vs tamoxifen (TAM) vs CMFVP + TAM for postmenopausal women with ER + operable breast cancer and positive axillary lymph nodes: An Intergroup study, Proc Am Soc Clin Oncol, 9, 24 Rose, 1980, Effects of adjuvant chemohormonal therapy on the ovarian and adrenal function of breast cancer patients, Cancer Res, 40, 4043 Rutqvist, 1993, Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen, J Natl Cancer Inst, 85, 1398, 10.1093/jnci/85.17.1398 1993, Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: The Scottish trial, Lancet, 341, 1293 Seidman, 1993, Lack of clinical cross-resistance of taxol (T) with anthracycline (A) in the treatment of metastatic breast cancer (MBC), Proc Am Soc Clin Oncol, 12, 63 Seidman, 1993, Phase II evaluation of taxotere (RP56976, NSC628503) as initial chemotherapy for metastatic breast cancer, Proc Am Soc Clin Oncol, 12, 63 Seidman, 1992, Activity of taxol with recombinant granulocyte colony stimulating factor (GCSF) as first chemotherapy (C) of patients (PTS) with metastatic breast cancer (MBC), Proc Am Soc Clin Oncol, 11, 59 Slevin, 1988, Who should measure quality of life, the doctor or the patient?, Br J Cancer, 57, 109, 10.1038/bjc.1988.20 Smith, 1993, The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in premenopausal women, J Clin Oncol, 11, 771, 10.1200/JCO.1993.11.4.771 Stevenson, 1989, Determinants of bone density in normal women: Risk factors for future osteoporosis?, Br Med J, 298, 924, 10.1136/bmj.298.6678.924 Stewart, 1989, Scottish adjuvant breast cancer trials: Results in pre-menopausal patients, 126, 10.1007/978-3-642-83337-3_18 Tannock, 1990, Management of breast and prostate cancer: How does quality of life enter the equation?, J Clin Oncol, 4, 149 Tormey, 1990, Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMF plus tamoxifen compared with CMF for premenopausal breast cancer patients: An Eastern Cooperative Oncology Group Trial, Cancer, 65, 200, 10.1002/1097-0142(19900115)65:2<200::AID-CNCR2820650203>3.0.CO;2-Q Trudeau, 1993, Phase II study of taxotere as first line chemotherapy for metastatic breast cancer (MBC). A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) study, Proc Am Soc Clin Oncol, 12, 64 Valagussa, 1987, Second malignancies after CMF for resectable breast cancer, J Clin Oncol, 5, 1138, 10.1200/JCO.1987.5.8.1138 Williams, 1986, The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer, Br J Cancer, 53, 629, 10.1038/bjc.1986.106 Yusuf, 1991, Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials, JAMA, 266, 93, 10.1001/jama.1991.03470010097038